Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05154955 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat
A Phase 2 study, sponsored by 10xBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT05154955: Completed Phase 2 study, sponsored by 10xBio.
NCT05154955 is a Phase 2 study that has completed, run by 10xBio. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05154955, a Phase 2 study, has completed, sponsored by 10xBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs. vehicle (placebo) for adults with excessive submental fat (SMF).
Primary Outcome
Change from Baseline after final treatment. CSFS is a 5 point scale, with a higher score indicating higher severity
Interventions
- DRUG 10XB-101 Solution for Injection
- DRUG 10XB-101 Vehicle Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2024-03-19 |
| Phase | Phase 2 |
What the finished NCT05154955 record still lists
NCT05154955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which 10XB-101 Solution for Injection is the first listed.
NCT05154955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05154955 about?
NCT05154955 is a clinical study titled "A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat". The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs. vehicle (placebo) for adults with excessive submental fat (SMF).
What is the current status of trial NCT05154955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2021-10-19. Estimated completion is 2024-03-19.
What interventions are being tested in trial NCT05154955?
The interventions under investigation include: 10XB-101 Solution for Injection (DRUG), 10XB-101 Vehicle Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT05154955?
This trial is sponsored by 10xBio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05154955's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI